IgAN、LN、または C3G を有する参加者における ADX-097 の安全性、PD、PK、および臨床活性を評価するための第 2 相試験
IgAN、LN、または C3G を有する 18 歳以上の男女参加者に皮下投与された ADX-097 の安全性、薬力学、薬物動態、および臨床活性を評価する第 2 相試験
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 16 Years or Older with Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G)
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Akebia Therapeutics
- 電話番号:16178446128
- メール:trials@akebia.com
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
All participants
-
Male or female participants aged ≥16 years.
-
uPCR ≥0.5 g/g (from the average of 3 first morning voids [FMVs]).
-
Screening eGFR ≥30 mL/min/1.73m2 calculated by the Chronic Kidney Disease Epidemiology Collaboration creatinine equation (CKD-EPI GFR).
-
Participants receiving a renin-angiotensin-aldosterone system (RAAS) inhibitor, sodium-glucose cotransporter-2 (SGLT2) inhibitor, sparsentan, or atrasenten must have been on a stable dose (at the maximum recommended dose according to local guidelines or maximum tolerated dose) for at least 8 weeks prior to Study Day 1 and the dose is projected to remain stable until completion of the study.
Participants with IgAN only
-
Kidney biopsy-proven diagnosis of IgAN with a kidney biopsy that is obtained within 10 years of Day 1 or within 5 years of Day 1 if the participant is known or suspected of also having diabetic nephropathy.
Participants with LN only
-
Clinical diagnosis of systemic lupus erythematosus (SLE)
-
Kidney biopsy-proven diagnosis of LN with a kidney biopsy that is obtained within 24 weeks of Day 1.
-
Diagnosis of active focal or diffuse LN class III or IV
Participants with C3G only
-
Kidney biopsy-proven diagnosis of C3G, either dense deposit disease (DDD) or complement component 3 glomerulonephritis (C3GN), with a kidney biopsy that is obtained within 52 weeks of Day 1.
-
Participants receiving mycophenolate mofetil (MMF) (or mycophenolic acid) or prednisone ≥10 mg/d or equivalent must have been on a stable dose for at least 12 weeks before Day 1 that is projected to remain stable until completion of the study.
Key Exclusion Criteria All participants
-
Rapidly progressive glomerulonephritis defined as a 50% decline in eGFR within 12 weeks of screening.
-
Concomitant significant renal disease other than IgAN, C3G, or LN per investigator discretion.
-
Participants with a history of and/or presence of anti-factor H antibodies at screening.
-
Uncontrolled hypertension with mean seated systolic blood pressure (BP) ≥160 mmHg or diastolic BP ≥100 mmHg based on the average of 2 measurements obtained at approximately 2-minute intervals after the individual has been sitting for 5 minutes.
-
Kidney, other solid organs, or bone marrow transplantation prior to or expected to occur during the study.
-
History of splenectomy.
Participants with IgAN only
-
Secondary forms of IgAN
-
Received systemic corticosteroid therapy, oral budenoside, or any other form of immunosuppressive therapy within 12 weeks before Day 1.
Participants with LN only
-
Lymphocyte count below 0.5 × 109/L at screening.
-
Received any of Cyclophosphamide, Calcineurin inhibitors, IV methylprednisolone, IV immunoglobulin therapy, Belimumab, Obinutuzumab and Rituximab treatments at protocol specified time points.
Participants with C3G only
-
Evidence of monoclonal gammopathy of unclear significance, infections, malignancy, autoimmune diseases, or other conditions to which C3G is secondary.
-
Received systemic corticosteroid therapy, eculizumab, iptacopan, pegcetacoplan, or any other form of immunosuppressive therapy ≤12 weeks before Day 1, except for MMF (or mycophenolic acid), which is permitted.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の:Open Label: ADX-097
Participants will be administered ADX-097 weekly once |
Subcutaneous Infusions |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Number of participants reporting treatment emergent adverse events (TEAEs)
時間枠:Up to 30 weeks
|
Up to 30 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from baseline in urine protein-to-creatinine ratio (uPCR)
時間枠:Baseline and up to 26 weeks
|
Baseline and up to 26 weeks
|
|
|
Change from baseline in estimated glomerular filtration rate (eGFR)
時間枠:Baseline and up to 26 weeks
|
Baseline and up to 26 weeks
|
|
|
Trough plasma Concentration of ADX-097
時間枠:At Days 1, 8, 22, 50, 78, 106, 134 and 176
|
Blood samples will be collected for the analysis of pharmacokinetic parameters at specified timepoints. |
At Days 1, 8, 22, 50, 78, 106, 134 and 176
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- ADX-097-CI-0053
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。